Watch for expansion-phase data from the ongoing Phase 1b study in Chinese NK patients, which will inform dosing regimen and regulatory path. The deal is early-stage with binary risk from clinical readouts and regulatory approval.
Price Chart
Executive Summary
NovaBridge's majority-owned ophthalmology subsidiary Visara in-licensed VIS-102 (HT006.2.2), a modified recombinant human nerve growth factor for neurotrophic keratitis, from Wuhan Hiteck. Visara pays $7.0M upfront/near-term and up to $104.0M in milestones plus single-digit royalties. Phase 1b data showed 50% complete corneal healing at highest dose vs 14% vehicle. This expands Visara's pipeline beyond retinal disease into ocular surface disease, but the deal is early-stage with no near-term revenue.
Key Facts
- Visara licensed exclusive worldwide rights (ex-Greater China) to VIS-102 (HT006.2.2) from Wuhan Hiteck Biological Pharma.
- Upfront and near-term milestone payment of $7.0 million; additional aggregate payments up to $104.0 million upon clinical and commercial milestones.
- Tiered royalties at a single-digit percentage of annual net sales on a country-by-country basis.
- Phase 1b data in severe NK: highest dose cohort achieved 50% complete corneal healing after 8 weeks vs 14% vehicle at Week 4.
- VIS-102 is Visara's second clinical-stage program, adding ocular surface disease to its retinal vascular focus.
- No subjects withdrew due to related adverse events; all treatment-related ocular AEs were mild.
Financial Impact
Upfront $7.0M cash outflow; potential milestone payments up to $104.0M; single-digit royalty on future sales. No revenue expected for years.
Risk Factors
- VIS-102 is investigational with only Phase 1b data; clinical failure or regulatory denial would impair value.
- Milestone payments up to $104M could strain cash if NovaBridge/Visara lacks funding.
- Competition from existing NK therapies (e.g., Oxervate) and other pipeline candidates.
- Reliance on Hiteck for manufacturing and Greater China rights; execution risk in global development.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-419669 |
| Document: 6-k_-_vs_102.htm | 0001193125-26-419669 |
| Document: 0001193125-26-419669-index-headers.html | 0001193125-26-419669 |
| Document: 0001193125-26-419669-index.html | 0001193125-26-419669 |
| Document: 0001193125-26-419669.txt | 0001193125-26-419669 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.49 | awaiting T+5 | — | $1.29 (−13.09%) |
Oct 25, 2026 2d ago | Press Release | $1.42 | awaiting T+5 | — | $1.29 (−8.80%) |
Oct 23, 2026 4d ago | 6-K | $1.37 | awaiting T+5 | — | $1.29 (−5.47%) |
Oct 13, 2026 14d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.29 (+0.39%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.29 (−27.25%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.29 (−27.25%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.29 (+32.20%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.29 (−32.20%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.29 (+32.20%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.29 (−27.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers